Sarafan ChEM-H
Showing 1-64 of 64 Results
-
Bria Castellano
Scientific Program Manager, Sarafan ChEM-H
Current Role at StanfordSarafan ChEM-H* Scientific Program Manager
*Chemistry, Engineering and Medicine for Human Health Research Institute -
Thomas J Cirino
Research Scientist, Animal Pharmacology, Innovative Medicines Accelerator (IMA)
BioIn Vivo Pharmacologist with expertise in CNS disorders including neurodegenerative disease, psychiatric disorders and pain.
-
Jean Dam
Research Scientist, Medicinal Chemistry, Innovative Medicines Accelerator (IMA)
Current Role at StanfordResearch Scientist at the MCKC
-
Marc Fleischmann
Project & Knowledge Management, Sarafan ChEM-H
Current Role at StanfordSolutions Wizard
-
Lynette Renae Haberman
Program Manager, Student Programs and Training, Sarafan ChEM-H
Current Role at StanfordProgram Manager, Student Programs and Training
-
Paul S Humphries
Alliance Director, Innovative Medicines Accelerator (IMA)
Current Role at StanfordAlliance Director, Stanford Innovative Medicines Accelerator (IMA)
-
Amy Jacobson
Director of Microbiome Therapies, Microbiome Therapies Initiative (MITI)
Current Role at StanfordSenior Scientific Program Manager, Sarafan ChEM-H and Stanford Innovative Medicines Accelerator
-
Pallavi Kompella
Lead Research Scientist, Animal Pharmacology, Innovative Medicines Accelerator (IMA)
BioPh.D. Pharmaceutical Sciences, The University of Texas at Austin, Texas
(American Foundation for Pharmaceutical Education Doctoral Fellow)
Fulbright Postdoctoral Scholar, Biomedical Research Institute of Malaga, Spain -
Elizabeth Ponder
Executive Director, Sarafan ChEM-H
BioElizabeth Ponder is a recognized leader in innovation and translation at the non-profit / for profit interface. Ponder has spent 15+ years building and scaling high-impact research organizations at the intersection of biomedical innovation, global health, and drug development — focused on ensuring the human health impact of transformative scientific discoveries while fostering the next generation of scientists.
As Executive Director of Sarafan ChEM-H, Ponder leads the institute's efforts to drive academic innovation and training at the interface of molecular disciplines. Ponder oversees Sarafan ChEM-H's research, education, and translational programs, guiding initiatives that foster collaboration, innovation, and impact.
With over a decade at Stanford, Ponder has changed the landscape of interdisciplinary molecular research and training. Under her leadership, the institute recruited 19 faculty representing the “scientific maverick” phenotype from diverse fields of molecular research, including 2022 Nobel Prize laureate Carolyn Bertozzi; established an innovative Ph.D. training program (NIH and philanthropy-funded) serving 150+ doctoral trainees since 2015; and designed and opened a 235,000 sq ft interdisciplinary research complex to house the institute. Her responsibilities include oversight of strategy, planning, and operations for the institute.
Most recently, Ponder oversaw the design and implementation of the “Nucleus" as a scalable model for democratizing access to cutting-edge research technologies and expertise and leveraged the Nucleus infrastructure to support a 6-year pilot program for strategic translational investments in new medicines based on Stanford discoveries, the Stanford Innovative Medicines Accelerator. The Nucleus has touched more than 600 research projects in 200+ faculty labs across the Stanford campus contributing to patents, publications, and new grant funding. The translational portfolio included 135+ projects, 8 successful exits to VC-backed biotechnology companies, and 9 clinical trials of experimental therapeutics, including 2 first-in-human trials of experimental therapeutics discovered and developed entirely within Stanford. Ponder also played a critical role in external relationship management for the portfolio, ranging from key philanthropic donors to biopharmaceutical partners and venture capital investors.
Ponder was recognized for leadership excellence at Stanford through selection for Leadership@Stanford (2025 cohort) and the 2023 Marsh O'Neill Award for exceptional support of Stanford's research enterprise.
Before joining Stanford, Ponder led policy, research, and training initiatives at the global health - biopharmaceutical industry interface. She served as Executive Director of the Wheeler Center for Emerging & Neglected Diseases at UC Berkeley where she designed and launched new programs addressing neglected disease research. She also served in roles of increasing responsibility in Scientific Affairs at BIO Ventures for Global Health (BVGH), where she provided scientific leadership to project teams and executive leadership, advancing BVGH's mission to increase innovative biotech participation in drug, vaccine, and diagnostic development for neglected diseases of the developing world.
Ponder completed her Ph.D. and postdoctoral research at Stanford in the department of microbiology and immunology, supported by an NSF National Science Foundation Graduate Research Fellowship and Stanford Dean’s postdoctoral fellowship. She published multiple peer-reviewed scientific publications focused on protease function and drug target potential in Plasmodium falciparum, the parasite that causes human malaria. Her early work in infectious diseases inspired her life-long passion for improving human health through scientific innovation. -
Arena See
Synthetic Microbiome Engineer, Microbiome Therapies Initiative (MITI)
Current Role at StanfordSynthetic Microbiome Engineer @ MITI
-
David Solow-Cordero
Associate Director, High-Throughput Screening, Innovative Medicines Accelerator (IMA)
Current Role at StanfordAssociate Director, High-Throughput Screening Knowledge Center, , Sarafan ChEM-H and Innovative Medicine Accelerator (IMA)
This high-throughput screening (HTS) laboratory allows Stanford researchers and others to discover novel modulators of targets that otherwise would not be practical in industry. The center incorporates instrumentation (purchased with NCRR NIH Instrumentation grant numbers S10RR019513, S10RR026338, S10OD025004, and S10OD026899), databases, compound libraries, and personnel whose previous sole domains were in industry.
Among our instrumentation are a fully automated Molecular Devices ImageXpress Micro Confocal High-Content fluorescence microplate imager, with live cell, fluidics and phase contrast options, an Echo 655 Acoustic Dispense, a Thermo integrated HTS robotic system, a Caliper Life Sciences SciClone ALH3000 and an Agilent Bravo microplate liquid handler, and the BMG Clariostarplus, Tecan Infinite M1000 and M1000 PRO and Molecular Devices FlexStation II 384 fluorescence, luminescence and absorbance multimode microplate readers.
We have over 180,000 small molecules for compound screens, 15,000 cDNAs for genomic screens, and whole genome siRNA libraries targeting the human genome (the siARRAY whole human genome siRNA library from Dharmacon, targeting 21,000 human genes) and the mouse genome (Qiagen mouse whole genome siRNA set V1 against 22,124 genes).
The HTSKC main screening lab is located in ChEM-H W008, the cell-based assay development lab is located in CCSR Room 0133-North Wing, between the Transgenic Mouse Facility, and the Stanford Genomics Facility.
